Can-Fite up 6% premarket on planned IND for pancreatic cancer candidate
Dr_Microbe/iStock via Getty Images
- Can-Fite BioPharma (NYSE:CANF) said it is preparing to submit an Investigational New Drug (IND) application to the US FDA for its pancreatic cancer candidate namodenoson.
- The Israeli biotech's stock is up 6% in premarket trading.
- With the submission, the company will begin an open-label phase 2 trial of namodenoson in pancreatic cancer patients who have been on at least one prior therapy.
- Can-Fite (CANF) is also enrolling patients in a phase 3 trial of namodenoson for hepatocellular carcinoma.
- Seeking Alpha's Quant Rating views the company as a strong sell.